News Analysis
A growing number of biotech, genomics, and medtech firms with ties to the Chinese Communist Party (CCP) are operating in the United States, raising concerns about medical and genetic data security.
Thinking About China
Opinion
CCP Investment in US Biopharm and Genomics Companies Raises Security Concerns
Technicians in a research and development lab at Chinese biotech company Coyote, which developed the Flash 20, a fast test for COVID-19, in Beijing, on Sept. 27, 2020. Greg Baker/AFP via Getty Images
Antonio Graceffo
Author
Antonio Graceffo, Ph.D., is a China economy analyst who has spent more than 20 years in Asia. Graceffo is a graduate of the Shanghai University of Sport, holds an MBA from Shanghai Jiaotong University, and studied national security at American Military University.
Author’s Selected Articles
